Latest Headlines
-
Otsuka Pharmaceutical Diagnostic Division Opens A New Laboratory In Tokyo To Advance Development Of Next-Generation Medical Devices
9/1/2025
Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces the establishment of a new research facility, the Tokyo Laboratory, located within the Mitsui Link Lab Shinkiba 2 Building in Koto-ku, Tokyo. The Tokyo Laboratory will serve as a new research base for Otsuka's Diagnostic Division.
-
CARB-X Backs Neonatal Sepsis Diagnostic Platform By QuantaMatrix
8/28/2025
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded QuantaMatrix Inc.
-
SmartLabs And Sonrai Launch Exclusive Partnership To Bring Advanced AI Capabilities To SmartLabs' Member Companies
8/28/2025
SmartLabs and Sonrai Analytics (Sonrai) today announced a global strategic partnership designed to bring Sonrai's next-generation AI capabilities directly into SmartLabs' network of advanced research centers.
-
Mount Sinai Researchers Use AI And Lab Tests To Predict Genetic Disease Risk
8/28/2025
When genetic testing reveals a rare DNA mutation, doctors and patients are frequently left in the dark about what it actually means. Now, researchers at the Icahn School of Medicine at Mount Sinai have developed a powerful new way to determine whether a patient with a mutation is likely to actually develop disease, a concept known in genetics as penetrance.
-
Alveo Technologies Successfully Fulfills Expanded CDC Milestone Agreement To Advance Its Rapid Molecular Test For Both Seasonal And Avian Influenza A(H5) In Humans
8/26/2025
Alveo Technologies, Inc. (Alveo), a leader in molecular sensing and diagnostics with its proprietary IntelliSense molecular detection technology, today announced that it has successfully fulfilled all objectives outlined in both its existing and follow-on expanded Agreement with the U.S Centers for Disease Control and Prevention (CDC) to further advance its rapid, molecular, point of care diagnostic, be.well to detect and differentiate between seasonal Influenzas A and B, as well as Influenza A(H5), a subtype of Influenza A commonly associated with Highly Pathogenic Avian Influenza, in humans.
-
AliveDx Registers MosaiQ®, Its Instrument For Multiplex Testing Of Autoimmune Diseases, Allergies And Beyond, As A Class II Exempt Device With The U.S. Food And Drug Administration (FDA)
8/26/2025
AliveDx, the global in-vitro diagnostics company dedicated to advancing patient care, today announced that its MosaiQ® instrument is registered with the U.S. Food and Drug Administration (FDA) as a Class II 510(k) exempt medical device.
-
BillionToOne's Northstar Select® Demonstrates Superior Sensitivity In Prospective Head-To-Head Validation Study Publication
8/26/2025
BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced publication of Validation of a liquid biopsy assay with increased sensitivity for clinical comprehensive genomic profiling1.
-
Deep Bio & Techcyte Partner To Integrate AI-Powered Prostate Diagnostics & Frozen Section On Techcyte Fusionx Platform
8/26/2025
Deep Bio, a global leader in AI-powered cancer diagnostics, today announced a strategic partnership with Techcyte to integrate Deep Bio’s prostate and frozen section algorithm into the RUO Techcyte Fusion platform, which is CE marked in Europe and RUO in the US.
-
Corewell Health And Quest Diagnostics To Enter Into Joint Venture Providing Enhanced Laboratory Services In Michigan
8/26/2025
Corewell Health and Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, have signed a definitive agreement to enter into a joint venture to expand access to innovative, quality and affordable laboratory services in Michigan.
-
WMI Partners With Arcadea Group
8/26/2025
Arcadea Group, a preeminent, long-term investor in global software businesses, today announced its acquisition of WMI, a leading provider of laboratory information management solutions in Brazil through its flagship Autolac software suite.